National Pharmaceutical Pricing Authority

The 2022 revision of the NLEM came after seven years. Most drugs that have been now brought into the NLEM include anti-infectives, anti-diabetics, anesthetics, etc

Drugs for ailments like chronic kidney disease, some high end antibiotics, anti-virals (anti-infectives), as well as some cancer drugs are likely to be brought under trade margin rationalization first

The petitioner, while seeking statutory backing to the Uniform Code of Pharmaceutical Marketing Practices (UCPMP), said that corruption in pharma marketing practices is yet unregulated in India

Drug pricing regulator NPPA has fixed the retail prices for 84 drug formulations, including those used for treatment of diabetes, headache and high blood pressure. The National Pharmaceutical Pricing Authority (NPPA) has also fixed the prices of formulations indicated to reduce increased cholesterol and triglycerides levels, among others. In exercise of the powers conferred by the Drugs (Prices Control) Order, 2013, the NPPA has fixed the retail prices of the medications, the regulator said in a notification. As per the order, a single tablet of Voglibose and (SR) Metformin Hydrochloride will cost Rs 10.47, excluding GST. Similarly, the price of Paracetamol and Caffeine has been fixed at Rs 2.88 per tablet. Besides, the price of one Rosuvastatin Aspirin and Clopidogrel capsule has been fixed at Rs 13.91. In a separate notification, NPPA said it has extended the revised ceiling price of liquid medical oxygen and oxygen inhalation (medicinal gas) till September 30 this year. The NP

A few weeks back, the pricing regulator had extended the price cap by a month after the earlier order validity ended in August

The NPPA had allowed firms to take a 10 per cent hike for their knee implant products last year

API prices have gone up by 25-30 per cent for some drugs in recent months

Glenmark had appealed to the pricing regulator in 2016 asking for a differential price for its Digihaler

A senior government official said the industry has been requesting for an amendment to allow them to implement the price change from the next batch.

The prices of APIs have gone up in the range of 5-88%

The strong performance of the sector is in line with our expectations: Icra

Price caps on sanitary products and hand washes are counterproductive

Insulin syringes 1 ml are being sold at maximum trade margins of 400% with needles and at 287% without needles

Drugs whose ceiling prices have been capped includes colon or rectal cancer treatment drug oxaliplatin

The drugs that have come under price revision are for chemotherapy, treating malaria and epilepsy, among others

Pharma firms have argued NPPA has failed to take into account annual inflation, while deciding drug prices